Llorenç Caballería

7.0k total citations · 2 hit papers
78 papers, 3.0k citations indexed

About

Llorenç Caballería is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Llorenç Caballería has authored 78 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Epidemiology, 40 papers in Hepatology and 23 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Llorenç Caballería's work include Liver Disease Diagnosis and Treatment (61 papers), Liver Diseases and Immunity (29 papers) and Diet, Metabolism, and Disease (22 papers). Llorenç Caballería is often cited by papers focused on Liver Disease Diagnosis and Treatment (61 papers), Liver Diseases and Immunity (29 papers) and Diet, Metabolism, and Disease (22 papers). Llorenç Caballería collaborates with scholars based in Spain, United Kingdom and Italy. Llorenç Caballería's co-authors include Albert Parés, Juan Rodés, Miquel Bruguera, Joan Rodés, Joan Caballería, Pere Torán‐Monserrat, Guillem Pera, Pilar Peris, Núria Guañabens and Françesca Pons and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Llorenç Caballería

75 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid

2006 518 citations Albert Parés, Llorenç Caballería et al. profile →
Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population

2021 171 citations Isabel Graupera, Llorenç Caballería et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Llorenç Caballería Spain	26	2.3k	2.1k	848	451	450	78	3.0k
Conrado Fernández‐Rodríguez Spain	25	1.5k 0.7×	1.5k 0.7×	476 0.6×	150 0.3×	242 0.5×	93	2.5k
Claudia O. Zein United States	17	1.7k 0.8×	1.0k 0.5×	381 0.4×	301 0.7×	746 1.7×	32	2.1k
Miguel Carneiro de Moura Portugal	21	2.0k 0.9×	1.1k 0.5×	295 0.3×	367 0.8×	680 1.5×	73	2.6k
Jill C. Keach United States	23	4.9k 2.1×	3.7k 1.8×	1.9k 2.3×	654 1.5×	1.4k 3.1×	33	6.1k
Kazunori Ida Japan	21	1.4k 0.6×	504 0.2×	853 1.0×	640 1.4×	767 1.7×	70	2.7k
R. Hultcrantz Sweden	26	1.1k 0.5×	1.1k 0.5×	904 1.1×	384 0.9×	130 0.3×	62	2.6k
Manuel Hernández‐Guerra Spain	24	1.4k 0.6×	1.2k 0.6×	790 0.9×	252 0.6×	308 0.7×	102	2.6k
Emilio Fábrega Spain	24	1.3k 0.5×	1.2k 0.6×	758 0.9×	243 0.5×	93 0.2×	96	2.1k
Goh Eun Chung South Korea	28	1.7k 0.7×	932 0.4×	674 0.8×	430 1.0×	744 1.7×	137	3.0k
J. Ludwig United States	26	2.0k 0.9×	2.0k 1.0×	1.0k 1.2×	209 0.5×	265 0.6×	55	3.3k

Countries citing papers authored by Llorenç Caballería

Since Specialization

Citations

This map shows the geographic impact of Llorenç Caballería's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Llorenç Caballería with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Llorenç Caballería more than expected).

Fields of papers citing papers by Llorenç Caballería

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Llorenç Caballería. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Llorenç Caballería. The network helps show where Llorenç Caballería may publish in the future.

Co-authorship network of co-authors of Llorenç Caballería

This figure shows the co-authorship network connecting the top 25 collaborators of Llorenç Caballería. A scholar is included among the top collaborators of Llorenç Caballería based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Llorenç Caballería. Llorenç Caballería is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Julián, María Teresa, Guillem Pera, Berta Soldevila, et al.. (2023). Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study. Frontiers in Endocrinology. 13. 19 indexed citations

Arteaga, Íngrid, Alba Martínez-Escudé, Llorenç Caballería, et al.. (2023). Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: Study protocol. PLoS ONE. 18(10). e0286586–e0286586. 7 indexed citations

Torán‐Monserrat, Pere, et al.. (2023). Risky Alcohol Consumption in the Elderly: Screening and Brief Intervention from Primary Care. The ALANE Study, a Randomized Clinical Trial. Beverages. 9(4). 100–100. 2 indexed citations

Julián, María Teresa, Guillem Pera, Berta Soldevila, et al.. (2021). Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. European Journal of Endocrinology. 184(4). 587–596. 18 indexed citations

Rodríguez‐Tajes, Sergio, Ángela Domı́nguez, J.A. Carrión, et al.. (2020). Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. Journal of Gastroenterology and Hepatology. 35(9). 1570–1578. 29 indexed citations

Caballería, Llorenç, Pere Torán‐Monserrat, & Joan Caballería. (2017). Marcadores de fibrosis hepática. Medicina Clínica. 150(8). 310–316. 12 indexed citations

Ginès, Pere, Isabel Graupera, Frank Lammert, et al.. (2016). Screening for liver fibrosis in the general population: a call for action. The Lancet. Gastroenterology & hepatology. 1(3). 256–260. 111 indexed citations

Fabrellas, Núria, et al.. (2013). Using Transient Elastography to Detect Chronic Liver Diseases in a Primary Care Nurse Consultancy. Nursing Research. 62(6). 450–454. 18 indexed citations

Caballería, Llorenç, Íngrid Arteaga, Guillem Pera, et al.. (2013). Factores de riesgo asociados a la presencia de hígado graso no alcohólico: un estudio de casos y controles. Medicina Clínica. 141(6). 233–239. 6 indexed citations

10.

Caballería, Llorenç, et al.. (2012). Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population. European Journal of Gastroenterology & Hepatology. 24(9). 1007–1011. 25 indexed citations

11.

Parés, Albert & Llorenç Caballería. (2010). Reply. Hepatology. 52(6). 2239–2240. 2 indexed citations

12.

Guañabens, Núria, Dacia Cerdá, Ana Monegal, et al.. (2010). Monthly ibandronate vs. weekly alendronate in the treatment of osteoporosis associated with primary biliary cirrhosis: similar efficacy but different adherence. Bone. 47. S204–S205. 3 indexed citations

13.

Parés, Albert, Dacia Cerdá, Ana Monegal, et al.. (2010). 184 MONTHLY IBANDRONATE VS. WEEKLY ALENDRONATE IN THE TREATMENT OF OSTEOPOROSIS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS: SIMILAR EFFICACY BUT DIFFERENT ADHERENCE. Journal of Hepatology. 52. S79–S79. 6 indexed citations

14.

Caballería, Llorenç, Guillem Pera, Maria Auladell, et al.. (2009). Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. European Journal of Gastroenterology & Hepatology. 22(1). 24–32. 183 indexed citations

15.

Caballería, Llorenç, Pere Torán‐Monserrat, Guillem Pera, et al.. (2008). Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study. BMC Gastroenterology. 8(1). 44–44. 14 indexed citations

16.

Boberg, Kirsten Muri, Giuseppe Rocca, Thore Egeland, et al.. (2002). Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology. 35(3). 652–657. 61 indexed citations

17.

Parés, Albert, Llorenç Caballería, Juan Rodés, et al.. (2000). Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. Journal of Hepatology. 32(4). 561–566. 202 indexed citations

18.

Parés, Albert, Ricard Tresserras, Isabel Núñez, et al.. (2000). Prevalencia y factores asociados a la presencia de esteatosis hepática en varones adultos aparentemente sanos. Medicina Clínica. 114(15). 561–565. 19 indexed citations

19.

Parés, Albert, et al.. (1999). Treatment of primary biliary cirrhosis. 1(1). 79–85. 1 indexed citations

20.

Parés, Albert, R. Deulofeu, A. Giménez, et al.. (1996). Serum Hyaluronate Reflects Hepatic Fibrogenesis in Alcoholic Liver Disease and Is Useful As A Marker of Fibrosis. Hepatology. 24(6). 1399–1403. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact